Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined i

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with

Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which i

HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 20

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform C

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limitin

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints w

Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phas

Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations fro

Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analys

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Multiple patients have survived substantially beyond expected median survival, including onepatient

SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagno

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Cali

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trial SAN JOSE, Cal

AVAX Technologies (OTCMKTS:AVXT - Get Free Report) and Anixa Biosciences (NASDAQ: ANIX - Get Free Re

Breast cancer vaccine met primary endpoints and generated protocol-defined immuneresponses in 74% of

Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% o

SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a

Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c

Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExp

Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limitin

Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than

The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer, who have failed st

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and m

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and m

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, R

  On Tuesday, 647 companies set new 52-week lows.

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.